These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29788203)

  • 1. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
    Kang SO; Kim SJ; Park S; Jang SI; Park EC
    Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea.
    Kim JY; Kim SJ; Nam CM; Moon KT; Park EC
    Eur J Public Health; 2018 Apr; 28(2):209-214. PubMed ID: 29579210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pharmaceutical cost containment policies on doctors' prescribing behavior: Focus on antibiotics.
    Han E; Chae SM; Kim NS; Park S
    Health Policy; 2015 Sep; 119(9):1245-54. PubMed ID: 26119997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward safer prescribing: evaluation of a prospective drug utilization review system on inappropriate prescriptions, prescribing patterns, and adverse drug events and related health expenditure in South Korea.
    Kim SJ; Han KT; Kang HG; Park EC
    Public Health; 2018 Oct; 163():128-136. PubMed ID: 30145461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea.
    Kim W; Koo H; Lee HJ; Han E
    Int J Health Policy Manag; 2022 Oct; 11(10):2198-2207. PubMed ID: 34814666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
    Bae G; Park C; Lee H; Han E; Kim DS; Jang S
    BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing trend of pioglitazone after safety warning release in Korea.
    Jeong HE; Cho SI; Oh IS; Baek YH; Shin JY
    Am J Manag Care; 2019 Nov; 25(11):e342-e348. PubMed ID: 31747239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea.
    Son KB
    BMC Public Health; 2020 May; 20(1):797. PubMed ID: 32460730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
    Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
    BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the effects of drug price reduction policies on older people in Taiwan.
    Chu HL; Liu SZ; Romeis JC
    Health Serv Manage Res; 2011 Feb; 24(1):1-7. PubMed ID: 21285360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Price-Volume Agreement Program in South Korea.
    Han E; Park SY; Lee EK
    Health Policy; 2016 Oct; 120(10):1209-1215. PubMed ID: 27519975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
    Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
    Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study.
    Ko SH; Kim DJ; Park JH; Park CY; Jung CH; Kwon HS; Park JY; Song KH; Han K; Lee KU; Ko KS;
    Medicine (Baltimore); 2016 Jul; 95(27):e4018. PubMed ID: 27399082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic utilization and cost-sharing for prescription drugs.
    Gibson TB; McLaughlin CG; Smith DG
    Adv Health Econ Health Serv Res; 2010; 22():195-219. PubMed ID: 20575234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
    Heald AH; Livingston M; Bien Z; Moreno GYC; Laing I; Stedman M
    Int J Clin Pract; 2018 Apr; 72(4):e13080. PubMed ID: 29537664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea.
    Park CM; Lee KS; Han E; Kim DS
    Health Policy; 2016 Jun; 120(6):590-5. PubMed ID: 27241339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.
    Fuksa L; Vocelka M; Vytrisalova M
    Health Policy; 2015 Sep; 119(9):1255-64. PubMed ID: 25929214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008.
    Currie CJ; Peters JR; Evans M
    Diabet Med; 2010 Jul; 27(7):744-52. PubMed ID: 20636954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.